GH Research to Present at ASCP Meeting on Breakthrough Depression Treatment

An announcement from GH Research ( (GHRS) ) is now available.

GH Research PLC announced its participation in the American Society of Clinical Psychopharmacology Annual Meeting from May 27-30, 2025, in Scottsdale, Arizona. The company will present findings on the safety and efficacy of GH001, a synthetic form of mebufotenin, in treating treatment-resistant depression. This presentation is part of the Pharmaceutical Pipeline session and highlights the results of a Phase 2b, double-blind, randomized controlled trial, potentially impacting the company’s position in the mental health treatment market.

The most recent analyst rating on (GHRS) stock is a Buy with a $31.00 price target. To see the full list of analyst forecasts on GH Research stock, see the GHRS Stock Forecast page.

Spark’s Take on GHRS Stock

According to Spark, TipRanks’ AI Analyst, GHRS is a Neutral.

GH Research’s stock score reflects significant challenges in financial performance, with consistent losses and negative cash flows. The company’s strong equity base and low debt provide some stability. Technical indicators show some short-term momentum, but valuation concerns persist due to the negative P/E ratio and lack of profitability.

To see Spark’s full report on GHRS stock, click here.

More about GH Research

GH Research PLC operates in the pharmaceutical industry, focusing on developing treatments for mental health disorders. The company is particularly involved in researching novel therapies for treatment-resistant depression, with a market focus on providing rapid and sustained relief for patients.

Average Trading Volume: 206,427

Technical Sentiment Signal: Strong Buy

Current Market Cap: $692.9M

For an in-depth examination of GHRS stock, go to TipRanks’ Stock Analysis page.